AI Engines For more Details: Perplexity Kagi Labs You
Cytotoxic Effects: Mitotane exerts its therapeutic effects by inhibiting the production of cortisol and other hormones by the adrenal cortex and by directly damaging adrenal cortical cells. This leads to a decrease in cortisol levels and a reduction in the size and activity of the adrenal glands, which is beneficial in the treatment of ACC.
Treatment of Adrenal Cortical Carcinoma: Mitotane is considered the mainstay of therapy for patients with ACC, particularly in cases where surgical resection of the tumor is not feasible or as adjuvant therapy following surgery. It helps control tumor growth and reduce the production of adrenal hormones, which can alleviate symptoms and improve overall survival in affected individuals.
Adrenal Insufficiency: Due to its suppressive effects on adrenal function, mitotane can induce adrenal insufficiency or hypocortisolism, a condition characterized by inadequate production of cortisol and other adrenal hormones. Patients receiving mitotane therapy may require replacement with glucocorticoid medications such as hydrocortisone to maintain normal physiological function.
Monitoring of Hormone Levels: During mitotane therapy, patients require close monitoring of adrenal hormone levels, including cortisol, aldosterone, and adrenal androgens, to assess treatment response and adjust medication dosages as needed. Regular blood tests and clinical evaluations are necessary to prevent complications associated with hormonal imbalances.
Side Effects: Common side effects of mitotane may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain, as well as neurological symptoms such as dizziness, headache, and fatigue. These side effects are often dose-dependent and may improve with dose adjustments or supportive care measures.
Hepatotoxicity: Mitotane has the potential to cause liver toxicity or hepatotoxicity, manifesting as elevated liver enzyme levels (transaminases) and, rarely, more severe liver dysfunction. Liver function tests should be monitored regularly during mitotane therapy, and treatment may need to be discontinued or adjusted if significant liver abnormalities occur.
Central Nervous System Effects: Mitotane can cross the blood-brain barrier and may cause central nervous system (CNS) side effects such as sedation, confusion, depression, and memory impairment. Patients should be advised to report any changes in mood or cognition to their healthcare providers for evaluation and management.
Teratogenicity: Mitotane is known to be teratogenic, meaning it can cause birth defects if used during pregnancy. Female patients of childbearing potential should use effective contraception during mitotane therapy and should be counseled about the risks of fetal harm. Pregnancy should be avoided for at least several months after discontinuation of mitotane treatment.
Drug Interactions: Mitotane may interact with other medications, including anticoagulants, corticosteroids, and certain antiepileptic drugs, potentially affecting their efficacy or safety. Patients should inform their healthcare providers about all medications, supplements, and herbal products they are taking to avoid potential drug interactions.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bacteroides uniformis | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
ADHD | 2.4 | 0.3 | 7 |
Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
Allergic Rhinitis (Hay Fever) | 1.9 | 0.4 | 3.75 |
Allergies | 3.3 | 1.9 | 0.74 |
Allergy to milk products | 1.7 | 0.7 | 1.43 |
Alopecia (Hair Loss) | 1.6 | 1.6 | |
Alzheimer's disease | 3.8 | 4.8 | -0.26 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.9 | 0.6 | 2.17 |
Ankylosing spondylitis | 2.3 | 0.6 | 2.83 |
Anorexia Nervosa | 1.4 | 2.6 | -0.86 |
Antiphospholipid syndrome (APS) | 1.2 | 1.2 | |
Asthma | 3.3 | 1.6 | 1.06 |
Atherosclerosis | 1.5 | 1.5 | 0 |
Atrial fibrillation | 3.2 | 1.3 | 1.46 |
Autism | 6.7 | 5.8 | 0.16 |
Autoimmune Disease | 0.3 | 0.7 | -1.33 |
Barrett esophagus cancer | 0.3 | -0.3 | |
benign prostatic hyperplasia | 0.3 | -0.3 | |
Biofilm | 0.3 | 0.3 | |
Bipolar Disorder | 1.2 | 1.1 | 0.09 |
Brain Trauma | 0.6 | 1.1 | -0.83 |
Cancer (General) | 1.2 | -1.2 | |
Carcinoma | 2.3 | 2 | 0.15 |
Celiac Disease | 2.3 | 1.9 | 0.21 |
Cerebral Palsy | 0.9 | 1.3 | -0.44 |
Chronic Fatigue Syndrome | 2.3 | 5 | -1.17 |
Chronic Kidney Disease | 2.8 | 2.5 | 0.12 |
Chronic Lyme | 0.6 | 0.8 | -0.33 |
Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 1.1 | 0.09 |
Chronic Urticaria (Hives) | 0.5 | 0.9 | -0.8 |
Coagulation / Micro clot triggering bacteria | 0.7 | 1.3 | -0.86 |
Cognitive Function | 2.3 | 1 | 1.3 |
Colorectal Cancer | 5.3 | 1.9 | 1.79 |
Constipation | 1.1 | 0.7 | 0.57 |
Coronary artery disease | 1.2 | 2.5 | -1.08 |
COVID-19 | 4.7 | 7.9 | -0.68 |
Crohn's Disease | 5.7 | 4.5 | 0.27 |
Cushing's Syndrome (hypercortisolism) | 0.8 | -0.8 | |
cystic fibrosis | 1 | -1 | |
deep vein thrombosis | 1 | 1.4 | -0.4 |
Denture Wearers Oral Shifts | 0.9 | 0.9 | |
Depression | 7 | 7.7 | -0.1 |
Dermatomyositis | 0.3 | 0.3 | |
Eczema | 0.5 | 1.7 | -2.4 |
Endometriosis | 2 | 1.1 | 0.82 |
Eosinophilic Esophagitis | 0.3 | -0.3 | |
Epilepsy | 2.3 | 1.9 | 0.21 |
erectile dysfunction | 0.5 | 0.5 | |
Fibromyalgia | 2.5 | 1.4 | 0.79 |
Functional constipation / chronic idiopathic constipation | 3.5 | 3.5 | 0 |
gallstone disease (gsd) | 2.2 | 0.7 | 2.14 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.1 | 0.5 | 1.2 |
Generalized anxiety disorder | 1.2 | 1.2 | 0 |
giant cell arteritis | 0.2 | -0.2 | |
Glioblastoma | 0.3 | -0.3 | |
Gout | 1.1 | 0.7 | 0.57 |
Graves' disease | 1.3 | 2.7 | -1.08 |
Gulf War Syndrome | 0.9 | 1.4 | -0.56 |
Halitosis | 0.6 | 0.3 | 1 |
Hashimoto's thyroiditis | 3.2 | 1 | 2.2 |
Heart Failure | 2.4 | 1.7 | 0.41 |
hemorrhagic stroke | 1 | 1 | |
Hidradenitis Suppurativa | 0.6 | 0.6 | |
High Histamine/low DAO | 1.3 | 0.3 | 3.33 |
hypercholesterolemia (High Cholesterol) | 0.2 | 0.3 | -0.5 |
hyperglycemia | 1.3 | 1.3 | 0 |
Hyperlipidemia (High Blood Fats) | 0.4 | 0.3 | 0.33 |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 4 | 2.9 | 0.38 |
Hypothyroidism | 0.2 | 0.4 | -1 |
Hypoxia | 2.2 | 2.2 | |
IgA nephropathy (IgAN) | 1.3 | 1.6 | -0.23 |
Inflammatory Bowel Disease | 4.6 | 6.2 | -0.35 |
Insomnia | 2.2 | 2.3 | -0.05 |
Intelligence | 1.3 | 1.3 | |
Intracranial aneurysms | 1.2 | 0.6 | 1 |
Irritable Bowel Syndrome | 4.7 | 4.1 | 0.15 |
ischemic stroke | 1.4 | 1.1 | 0.27 |
Liver Cirrhosis | 4.8 | 3.6 | 0.33 |
Long COVID | 3.1 | 4.7 | -0.52 |
Low bone mineral density | 0.8 | -0.8 | |
Lung Cancer | 0.1 | 1.3 | -12 |
Mast Cell Issues / mastitis | 0.3 | 0.6 | -1 |
ME/CFS with IBS | 0.5 | 1.2 | -1.4 |
ME/CFS without IBS | 0.5 | 1.9 | -2.8 |
membranous nephropathy | 0.3 | 0.3 | |
Menopause | 0.3 | 0.7 | -1.33 |
Metabolic Syndrome | 4.4 | 5.1 | -0.16 |
Mood Disorders | 6.8 | 6 | 0.13 |
multiple chemical sensitivity [MCS] | 1.1 | 0.1 | 10 |
Multiple Sclerosis | 4.4 | 5.3 | -0.2 |
Multiple system atrophy (MSA) | 0.5 | 0.4 | 0.25 |
myasthenia gravis | 0.3 | 0.7 | -1.33 |
neuropathic pain | 1.4 | -1.4 | |
Neuropathy (all types) | 0.6 | 1 | -0.67 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.6 | 2.8 | -0.08 |
NonCeliac Gluten Sensitivity | 1 | 0.3 | 2.33 |
Obesity | 5.8 | 6.3 | -0.09 |
obsessive-compulsive disorder | 4 | 2.8 | 0.43 |
Osteoarthritis | 1.4 | 1 | 0.4 |
Osteoporosis | 1.3 | 1.6 | -0.23 |
pancreatic cancer | 0.3 | 0.3 | 0 |
Parkinson's Disease | 6.9 | 5.4 | 0.28 |
Polycystic ovary syndrome | 5.5 | 2.5 | 1.2 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
Premenstrual dysphoric disorder | 0.4 | 0.4 | 0 |
primary biliary cholangitis | 0.9 | 1.3 | -0.44 |
Primary sclerosing cholangitis | 1.2 | 2.1 | -0.75 |
Psoriasis | 2.4 | 3.1 | -0.29 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.6 | 3.5 | 0.31 |
Rosacea | 0.9 | 0.7 | 0.29 |
Schizophrenia | 3.6 | 2.4 | 0.5 |
scoliosis | 0.3 | 0.3 | 0 |
Sjögren syndrome | 0.9 | 2.2 | -1.44 |
Sleep Apnea | 1.3 | 1.6 | -0.23 |
Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 1.1 | |
Stress / posttraumatic stress disorder | 2.2 | 2.2 | 0 |
Systemic Lupus Erythematosus | 2.2 | 1.7 | 0.29 |
Tic Disorder | 1.1 | 0.9 | 0.22 |
Tourette syndrome | 1 | 0.3 | 2.33 |
Type 1 Diabetes | 2.9 | 2.1 | 0.38 |
Type 2 Diabetes | 5.3 | 5.5 | -0.04 |
Ulcerative colitis | 3.6 | 5.1 | -0.42 |
Unhealthy Ageing | 3.7 | 2 | 0.85 |
Vitiligo | 1.9 | 1.1 | 0.73 |